Get insights on GlycoMimetics Inc's Phase 3 study results for uproleselan in R/R AML patients. Explore survival rates, adverse events, and future analyses.
Twist Bioscience reports strong Q2 earnings, with sales up 25% YoY to $75.3M and orders increasing by 45%. Gross margin expands to 41%. Fiscal year guidance was raised, and William Blair sees continued growth momentum. Analysts reaffirm Outperform ratings.
Amneal Pharmaceuticals settles $270 million opioid crisis agreement, offering cash and naloxone spray. Boosted by strong Q1 earnings, the company reaffirms fiscal guidance.
Preliminary results of AEON Biopharma's Phase 2 trial for chronic migraine treatment reveal no significant improvement over placebo. Despite anticipated reductions in monthly migraine days, statistical significance was not reached, prompting a review of development strategies and financial measures.
Owens & Minor impresses with Q1 results: adjusted EPS of $0.19, and sales of $2.61B (up 4% Y/Y). Patient Direct revenue reaches $638M (up 5% Y/Y). CEO Edward Pesicka highlights growth strategies and reaffirms 2024 revenue guidance of $10.5-$10.9 billion and adjusted EPS of $1.40-$1.70.
Unlocking global access to Bacillus Calmette-Guerin (BCG) for cancer therapy. ImmunityBio partners with Serum Institute to expand BCG supply. FDA-approved Anktiva plus BCG for bladder cancer.
Reduced prices on Wegovy and Mounjaro at British pharmacies amid growing competition. Simple Online Pharmacy slashes Mounjaro starter doses to £149 from £179, catering to high demand.